The Human Carbonic Anhydrase II in Platelets: An Underestimated Field of Its Activity

Maciej Jakubowski, Ewa Szahidewicz-Krupska, and Adrian Doroszko

Department of Internal Medicine, Occupational Diseases and Hypertension, Wroclaw Medical University, Borowska 213, 50-556 Wroclaw, Poland

Correspondence should be addressed to Maciej Jakubowski; maciekjak@gmail.com

Received 15 April 2018; Accepted 24 May 2018; Published 28 June 2018

1. Carbonic Anhydrases

Carbonic anhydrases constitute a group of enzymes that catalyse reversible hydration of carbon dioxide leading to the formation of bicarbonate and proton. Carbonic anhydrase is present in prokaryotic and eukaryotic cells. Genetically they belong to seven subgroups (α, β, γ, δ, ζ, η, θ) that are not evolutionarily related [2–4]. There are 15 carbonic anhydrase isoforms in humans (belonging to the α subgroup) [5]. They occur in various tissues in the cytoplasm, cell membrane, and mitochondria, or as extracellular enzymes (e.g., breast milk) [6]. Carbonic anhydrases (CAs) are almost ubiquitously present in human cells. The members of the CAs family play a role in pH regulation, gas exchange, and ion transport, as well as urine acidification, cerebrospinal fluid secretion, ocular fluid production, bone resorption, fatty acid metabolism, testicular fluid production, and many others [7].

1.1. Carbonic Anhydrase Deficiency

Carbonic anhydrase deficiency has no clinically relevant consequences [8], but CAII deficiency usually results in osteoporosis, renal tubular acidosis, and brain calcification [9, 10]. CAIII deficiency in skeletal muscles seems to play an important role in pathogenesis of myasthenia gravis [11, 12]. The carbonic anhydrase VA deficiency may present as early-onset liver failure with hyperammonemia, hyperlactatemia, and ketonuria [13]. CAXII deficiency may promote hyponatremic dehydration and rhabdomyolysis after intense physical exercises [14]. The effectiveness of carbonic anhydrase may be also altered by autoantibodies. Ignaki et al. demonstrated in 1991 that anti-carbonic anhydrase autoantibodies (aCAAs) are present in serum of 32% patients with systemic lupus erythematosus, in 21% of patients with Sjögren’s syndrome, but not in healthy volunteers. They showed that aCAAs have affinity to epidermal cells, hair follicles, sweat glands, and renal tubular cells [15]. Moreover, in 2007, it was presented that also in rheumatoid arthritis there are present aCAAs in serum, showing affinity to bind to carbonic anhydrase III in synovial membranes [16]. Up to date aCAAs have been described in patients with rheumatoid disorders (rheumatoid arthritis, Behçet’s disease, lupus erythematosus, polymyositis, systemic sclerosis, and Sjögren syndrome) [16–18], digestive tract disorders (idiopathic chronic pancreatitis, primary biliary
cirrhosis, autoimmune cholangitis, and gastric cancer) [18, 19], endometriosis [18], Grave’s disease [20], acute myeloid leukaemia [21], renal tubular acidosis [22] (significant influence on pathogenesis proved in the animal model of Sjögren’s syndrome [23]), and end-stage kidney disease [24]. Moreover, autoantibodies against carbonic anhydrase II were proved to play an important role in pathogenesis of retinopathy [25] and these against CAVI seem to induce dry eye syndrome in Sjögren’s syndrome [26, 27]. Interestingly, the autoantibodies against carbonic anhydrase II might be produced in humans due to cross-reactivity with carbonic anhydrase of Helicobacter pylori [28].

Carbonic anhydrases (CAs) have become an interesting enzyme for clinicians when first drugs inhibiting this enzyme established promising group of diuretics. Acetazolamide was introduced into clinical practice in 1956 as a first nonmercurial diuretic. Among “classic” carbonic anhydrase inhibitors also methazolamide, ethoxzolamide, and dichlorphenamide were applied in congestive heart failure treatment. Nowadays, more preferable are the next-generation diuretics (loop, thiazide, thiazide-like diuretic, and aldosterone antagonists), but most of them still exhibit different magnitude of carbonic anhydrase inhibition [38]. Acetazolamide remains a useful drug in case of intracranial hypertension [39], improving sleep quality (reducing the apnea-hypopnea index in both obstructive sleep apnea and healthy trekkers) [40] and reducing the risk of mountain sickness at high altitudes [41]. Topical dorzolamide and brinzolamide and in some cases systemic acetazolamide are commonly used for reduction of intraocular pressure in glaucoma [42]. Topiramate and zonisamide are anticonvulsants with a multiple mechanism of action among which is also carbonic anhydrase inhibition. Not only does this effect seem to be important in the main (antiepileptic) activity of this drug, but also it might result in weight loss. It is regarded as a side effect but may be the basis for designing the new antiobesity drugs [38]. Moreover, acetazolamide is also proved to be effective in seizure treatment [43]. Induced by hypoxia, overexpression of carbonic anhydrase IX in neoplastic cells may produce acidosis and thus reduce the effectiveness of chemotherapies [38]. Inhibition of carbonic anhydrase IX improves effects of cisplatin in small cell lung cancer [44].

2. Carbonic Anhydrase II

Carbonic anhydrase II (CAII) is a cytoplasmic enzyme with a very high affinity for sulphonamides and high catalytic activity (for structure see Figure 1.). It is one of the fastest, working enzymes in the human body, 10^6 cycles of enzyme per second [45]. CAII is present in numerous tissues (e.g., erythrocytes, eye, gastrointestinal tract, bone osteoclasts, kidney, lung, testis, and brain) and it constitutes a possible drug target in some diseases (glaucoma, oedema, epilepsy, and attitude sickness). However, so far it has been mostly studied in the red blood cells and has been extracted from them for the purpose of in vitro studies [5].

The gene for human CAII is located on the chromosome 8q22 [46]. The diseases associated with CAII include the following: Autosomal Recessive Osteopetrosis Type 3 with Renal Tubular Acidosis (ARO3, OPTB3), which commonly
manifests in early infancy with macrocephaly, feeding difficulties, evolving blindness and deafness, bone marrow failure, severe anaemia, and hepatosplenomegaly. Deafness and blindness are generally thought to represent effects of pressure on nerves. OPTB3 is associated with renal tubular acidosis and cerebral calcification (marble brain disease) and in some cases with mental retardation [47]. Among its related pathways is vitamin D-receptor mediated regulation of genes involved in osteoporosis [48].

Numerous compounds have been demonstrated to modify carbonic anhydrase activity. They are physiological substances, drugs currently used in clinical practice and other chemicals tested ex vivo in laboratories. Potential CAII activators physiologically present in human organism include biogenic amines (histamine, catecholamines, and serotonin) and amino acids (phenylalanine and histidine) [49]. Most drugs inhibiting carbonic anhydrase are sulphonamides (over 20 FDA approved drugs including diuretics like hydrochlorothiazide, indapamide, chlortalidone, and furosemide) [50, 51]. There is a wide variety of substances tested in laboratory conditions for their CA activatory and inhibitory properties [5, 52].

The aim of this review article was to collect available data regarding studies on carbonic anhydrase in platelets and concerning the influence of carbonic anhydrase regulators on platelet function. Taking into account limited number of studies directly analyzing carbonic anhydrase properties in platelets, a secondary objective was to analyze the involvement of drugs regulating CAII in platelet pathophysiology and to discuss hypothetical contribution of platelet carbonic anhydrase in these drug-platelet interactions.

### 3. Platelet Carbonic Anhydrase

The first statements of CAII in platelets were made 60 years ago [53] and its more accurate characterization was created in the ’80s of the last century [54]. CAII, by catalysing the formation of $\text{H}^+$ and $\text{HCO}_3^-$, reduces the cytosol pH of the platelet [55]. The reaction products can be excreted outside the plasma membrane – $\text{H}^+$ is being exchanged for $\text{Na}^+$ whereas $\text{HCO}_3^-$ for $\text{Cl}^-$ (Figure 2).

The exact role of CAII in platelet physiology requires more detailed research. A question arises whether their products play a direct role in platelet physiology or enhance the transmembrane ion exchange, sodium and chloride influx. So far there has been no clinical case presented in the PubMed database that describes CAII deficiency in platelets and, consequently, the effects of this deficiency on the phenotype. The only available case is the description of a murine mutation located in the direct proximity to the CAII gene locus, which affected both platelet morphology and function [56].

The CAII activity in platelets has been hypothesized since Akkerman et al. described proton efflux from platelets following thrombin stimulation [57, 58]. Siffert et al. verified the presence of $\text{CO}_2$ hydration in platelets, subsequently proved that this process may be inhibited by ethoxzolamide, and showed that examined enzyme kinetics strictly corresponds with carbonic anhydrase II [54]. Afterwards, ethoxzolamide was shown to reduce the thrombin stimulated aggregation by about 20%-40% [59, 60]. Similar result was achieved by the removal of $\text{CO}_2$ from platelets environment, which additionally confirms the importance of carbon dioxide hydration in the aggregation process [59].

#### 3.1. Effect of Carbonic Anhydrase Activators on Platelet Function

Adrenaline is CAII agonist [61] and it can sensitize platelets to thrombin by induction of CAII activity [62, 63]. Adrenaline stimulates platelet carbonic anhydrase directly or by enhancing the membrane HCO$_3^-$ /Cl$^-$ exchange since such subthreshold doses of adrenaline (in concentrations which do not initiate aggregation) added to platelets are capable of increasing the chloride concentration in platelet cytosol [55]. Not only does a CAII inhibitor, acetazolamide, reduce resting and adrenaline-induced chloride concentration in platelets, but it also abolishes the synergism of thrombin and low concentration of adrenaline [63]. The proaggregatory effect of adrenaline is also abolished by another CAII inhibitor, chlortalidone. Furthermore, the ability of adrenaline to initiate platelet aggregation has been demonstrated to be directly proportional to the activity of platelet carbonic anhydrase [64].

Serotonin is an activator of carbonic anhydrase [49], which is also a poor agonist for platelet aggregation [65]. Interestingly, it enhances adrenaline, adenosine diphosphate (ADP) and collagen induced aggregation [65]. Furthermore, while being hyperreactive to adrenaline alone or adrenaline+serotonin, platelets present increased binding affinity for serotonin [65]. This observation may be clinically important as in an in vivo dog model serotonin plasma level was increased in stress conditions and it was suspected to significantly interplay with the evolution of an occlusive coronary thrombus [66], which was verified in human observation trial where high plasma serotonin level was associated.
with presence of coronary artery disease and future cardiac events [67]. This effect seems to be mediated through platelet 5-HT (5-hydroxytryptamine) receptors as saporregl (a 5-HT\(_2\) receptors antagonist) limits platelet aggregation [68–70]. To the best of our knowledge, the possible participation of direct serotonin influence on platelet carbonic anhydrase has not been evaluated.

The selective serotonin reuptake inhibitors (SSRI), fluoxetine, sertraline, and citalopram, are potent activators of carbonic anhydrase II [71] and therefore they may be suspected of proaggregatory properties. Nevertheless, another SSRI, paroxetine, decreases intraplatelet serotonin storage and at the same time lowers platelet activation [72]. Similarly, sertraline and citalopram also limit platelet aggregation [73, 74]. Fluoxetine was to decrease platelet aggregability in the case of a 49-year-old man [75]. Therefore, SSRI effect on platelet function may be the balance between their direct action on platelets and the result of decreased platelet serotonin content. Nevertheless, the impact of this group of drugs on both thrombotic [76] and bleeding events is not substantial [77].

Histamine is a poor carbonic anhydrase II activator [52] present in humans platelets and it plays an important role in modulating platelet function. Histamine does not initiate platelet aggregation by itself, but it increases platelet sensitivity to aggregation agonists like ADP, thrombin, collagen, arachidonic acid [78], and adrenaline [79]. In a clinical model of increased histamine release, patients with chronic urticaria, higher platelet activity was observed when compared to healthy controls: increased levels of soluble P-selectin in one study [80] and both enhanced aggregation in response to ADP and increased soluble P-selectin levels compared to healthy population in another paper (both parameters were strongly and positively correlated with the Urticaria Severity Score) [81]. The mechanism of histamine impact on platelet pathophysiology is not fully understood. Histamine proaggregatory properties seem to result from H\(_1\) receptor stimulation (located in platelet membrane [82]). However, involvement of histamine in intracellular metabolism is also suggested [78], which was the subject matter of some studies [79, 83, 84]. Interestingly, there are no studies verifying whether CA inhibitors attenuate histamine affect platelet aggregation and if such an inhibition may be useful, e.g., in chronic urticaria management.

Histidine, phenylalanine, and carnosine (β-alanine-histidine dipeptide) are carbonic anhydrase activators [52]. Data regarding effect of histidine and carnosine on platelet function are not consistent. In some studies, histidine was verified to be an inhibitor of ADP-induced platelet aggregation [85] or spontaneous platelet aggregation and thromboxane B\(_2\) (TxB\(_2\)) formation [86], but in others it demonstrated both slight proaggregative activity (50% of the patients) and antiaggregatory activity (the other 50% of patients) [87]. Similarly, in one study carnosine slightly stimulated ADP-induced aggregation [87], but in another it enhanced platelet aggregation only in patients with a low rate of aggregation, but inhibited platelet aggregation in patients with high index of aggregation [88]. There are hardly any available data on phenylalanine influence on platelet function; in a single study phenylalanine methyl ester inhibited ADP-induced platelet aggregation. Interestingly, similar results were observed with histidine methyl ester, but not with pure histidine (no inhibition) [89].

There are no available papers analyzing histidine, phenylalanine, and carnosine influence on CAII in platelets. Nevertheless, while analyzing their action profile, they do not appear to act on platelets through CAII.

### 3.2 Diuretics as CAII Inhibitors

Systemic use of acetazolamide is dedicated for altitude sickness treatment and prevention. Primarily, it reverses hypocapnic alkalosis occurring due to ventilatory response to hypoxemia, but the exact mechanism of its beneficial action seems to be more complex and is not fully recognized [41]. Moreover, in people exposed to high altitudes, thrombosis is a proposed mechanism of several complications as in autopsy many megakaryocytes were present in the lungs of people diagnosed with pulmonary edema and in one case they were also accompanied by thrombi in the kidneys and liver [90]. Nevertheless, at high altitude platelets present increased adhesiveness [91], but decreased aggregation in response to ADP, adrenaline, and collagen [92, 93] so eventual benefit of acetazolamide antiaggregatory properties remains uncertain.

Diuretics commonly used in clinical practice (hydrochlorothiazide, chlortalidone, indapamide, furosemide, and bumetanide) are well-established carbonic anhydrase inhibitors [51]. Thiazide-like diuretics, indapamide and chlortalidone, are widely used in cardiovascular medicine. They are proved to prevent cardiovascular events (CVE) and reduce all-cause mortality. The CVE prophylactic effect exceeds the benefits of lowering blood pressure. The difference was revealed when this thiazide-like diuretics were compared with thiazide-type diuretics [94]. The important differences in activity between these two groups of drugs regard platelet inhibition, which is much more intense in thiazide-like than thiazide-type diuretics as shown in work by Rendu et al. comparing indapamide and hydrochlorothiazide properties [95]. Furthermore, the platelet inhibition by thiazide-like diuretics seems to be carbonic anhydrase dependent [64].

Loop diuretics, furosemide and bumetanide, are loop diuretics potent to inhibit carbonic anhydrase II activity [51]. In one clinical study, furosemide was shown to inhibit ADP-induced platelet aggregation both ex vivo and after intravenous infusion [96] and in another study furosemide inhibited in vitro both ADP- and AA-induced aggregation [97]. Bumetanide was also shown to inhibit adrenaline-induced aggregation [63]. The mechanism of influence of loop diuretics on platelets remains unclear and the involvement of carbonic anhydrase may be expected.

### 3.3 Physiological Nitrogen Compounds versus Platelet Carbonic Anhydrase II Function

Platelet aggregation may be inhibited by nitric oxide (NO). However there is a controversy about possible significance of this dependence since the extra-platelet NO concentration is low and it seems to be no expression of nitric oxide synthase in platelets [33, 34]. Nevertheless, the effect of NO on platelets is mediated...
through the activation of guanylyl cyclase to produce cyclic guanosine monophosphate (cGMP) [98, 99]. Interestingly, carbonic anhydrase II was found to catalyse generation of nitric oxide form nitrite [100], which may be an additional origination of intra-platelet NO. This reaction is significantly enhanced by both decreased pH and dorzolamide, which are inhibitors of CAII main activity [100]. On the other hand, other research groups provide evidence negating this CA activity [36].

Nitrite is a platelet inhibitor in whole blood [101], but added to platelets suspended in platelet rich plasma it does not inhibit platelet aggregation [102] or activate soluble guanylate cyclase (sCG) [36]. It does not produce increased intraplatelet nitrite concentration [103], either. Therefore it (in these conditions) cannot rich cytosolic enzymes like carbonic anhydrase II.

Platelet supplementation with S-Nitrosocysteine (SNC), a NO donor, also provides intraplatelet NO\(_2^{-}\) formation and leads to platelet sCG activation [35, 36, 103]. Interestingly, SNC aggregation inhibition is not mediated by sCG activation. SNC also presents direct cyclooxygenase (COX) inhibiting properties, but an involvement of one more mechanism is postulated as it produces complete blockage of AA-induced aggregation, when TxB\(_2\) formation is only partially decreased [103]. Therefore, SNC is supposed to be involved in one more mechanism modulating platelet function, which may be CA. This thesis of CA contribution may be supported by observation that SNC produces increased intraplatelet nitrite formation [103]. CA II is proven to catalyse opposite reaction; it can produce S-nitrosothiols from inorganic nitrite [36] (Figure 3).

Nitrate is able to bind to carbonic anhydrase active site [104], but not it cannot be utilized to form S-nitrosothiols as nitrite can be [105]. It can inhibit platelet aggregation in whole blood, but the mechanism remains unclear [101].

3.4. Other Drugs Potentially Inhibiting Platelet Carbonic Anhydrase II. An experiment considering influence of N-hydroxyurea on platelet activity was performed by Lahiri at al. in chronic myelogenous leukaemia. There were at least three patterns of response to hydroxyurea, no response, partial aggregation inhibition, and “de-aggregation”. Interestingly, both aggregation inhibition and “de-aggregation” were only partially reversible by ODQ (1H-(1,2,4)Oxadiazolo(4,3-a)quinoxalin-1-one), which indicates involvement of other mechanism than postulated by authors NO release stimulating cGMP formation [106]. The inhibition of platelet carbonic anhydrase II by N-hydroxyurea may be possible [107].

Coumarin and its derivatives are carbonic anhydrase inhibitors and substrates [108, 109]. Unfortunately, there is no information on acenocoumarol and warfarin (two coumarin derivatives widely used as anticoagulant drugs [110]) regarding their individual influence on carbonic anhydrase. Nevertheless, these two drugs do not seem to inhibit platelet carbonic anhydrase in humans as both of them enhance platelet activity [111, 112].

A substantial part of nonsteroid anti-inflammatory drugs (NSAIDs) present anti-CAII activity. Celecoxib [113, 114] and valdecoxib [115], but not rofecoxib [114], meloxicam, piroxicam, and lornoxicam [116], are carbonic anhydrase II inhibitors. Diclofenac, which does not possess sulphonamide moiety, is not active against CA [116]. Flurbiprofen is a weak carbonic anhydrase II inhibitor whereas ibuprofen and indomethacin are even much less active against this enzyme [117]. In two papers by Puscas et al. indomethacin was said to be an agonist of CA, but this conclusion was reached after indomethacin limited inhibitory effect of acetazolamide on carbonic anhydrase [118, 119] and it was uncertain whether it was indeed CA agonist or just weaker than acetazolamide CA inhibitor competing for a binding site. Acetylsalicylic acid (ASA) is a noncompetitive carbonic anhydrase II inhibitor [120], but this activity may be associated with adjusting environmental pH by ASA [121]. The effect of other NSAID on platelet function does not seem to depend on CAII regulation, but exclusively on COX-1 inhibition. A nonspecific COX inhibitor naproxen, but not COX-2 selective inhibitor celecoxib inhibits both collagen and arachidonate induced platelet aggregation [122]. Nevertheless, in a recent report we provided evidence that interindividual variability in \textit{in vitro} platelet responsiveness to acetylsalicylic acid may be associated with carbonic anhydrase II concentration. Briefly, ASA low-responders presented increased intraplatelet CAII concentration and more intense baseline arachidonic acid induces aggregation compared to ASA sensitive individuals [123]. Among the CAII-dependent mechanisms modifying the platelet responsiveness, the pH changes of platelet cytosol leading to impaired acetylation of cyclooxygenase by ASA are noteworthy. This in turn could affect the antiplatelet effect of ASA as well as platelet inflammatory activity and energetic metabolism (Figure 4).

To conclude, the role of carbonic anhydrase II in cardiovascular medicine is still underestimated and requires further in-depth studies.
Conflicts of Interest

The authors declare that they have no conflicts of interest.

References

[1] Nomenclature Committee of the International Union of Biochemistry and Molecular Biology (NC-IUBMB), “In consultation with the IUPAC-IUBMB Joint Commission on Biochemical Nomenclature (JCBN) Enzyme Nomenclature Recommendations of the Nomenclature Committee of the International Union of Biochemistry and Molecular Biology on the Nomenclature and Classification of Enzymes by the Reactions they Catalyse IUBMB Enzyme Nomenclature EC 4.2.1.1,” EC 4.2.1.1 created 1961, modified 2016, http://www.chem.qmul.ac.uk/iubmb/enzyme/EC4/2/1/1.html.

[2] Y. Xu, L. Feng, P. D. Jeffrey, Y. Shi, and F. M. M. Morel, “Structure and metal exchange in the cadmium carbonic anhydrase of marine diatoms,” *Nature*, vol. 452, no. 6, pp. 56–62, 2008.

[3] S. Del Prete, D. Vullo, G. M. Fisher et al., “Discovery of a new family of carbonic anhydrases in the malaria pathogen Plasmodium falciparum - The η-carbonic anhydrases,” *Bioorganic & Medicinal Chemistry Letters*, vol. 24, no. 18, pp. 4389–4396, 2014.

[4] S. Kikutani, N. Nakajima, C. Nagasato, Y. Tsuji, A. Miyatake, and Y. Matsuda, “Thylakoid luminal θ-carbonic anhydrase critical for growth and photosynthesis in the marine diatom,” *Proceedings of the National Academy of Sciences of the United States of America*, vol. 113, no. 35, pp. 9828–9833, 2016.

[5] V. Alterio, A. di Fiore, K. D’Ambrosio, C. T. Supuran, and G. de Simone, “Multiple binding modes of inhibitors to carbonic anhydrases: how to design specific drugs targeting 15 different isoforms?” *Chemical Reviews*, vol. 112, no. 8, pp. 4421–4468, 2012.

[6] C. T. Supuran and A. Scozzafava, “Carbonic anhydrases as targets for medicinal chemistry,” *Bioorganic & Medicinal Chemistry*, vol. 15, no. 13, pp. 4336–4350, 2007.

[7] M. Imtaiyaz Hassan, B. Shajee, A. Waheed, F. Ahmad, and W. S. Sly, “Structure, function and applications of carbonic anhydrase isozymes,” *Bioorganic & Medicinal Chemistry*, vol. 21, no. 6, pp. 1570–1582, 2013.

[8] A. G. Kendall and R. E. Tashian, “Erythrocyte carbonic anhydrase I: Inherited deficiency in humans,” *Science*, vol. 197, no. 4302, pp. 471–472, 1977.

[9] K. J. Borthwick, N. Kandemir, R. Topaloglu et al., “A phenocopy of CAII deficiency: A novel genetic explanation for inherited infantile osteopetrosis with distal renal tubular acidosis,” *Journal of Medical Genetics*, vol. 40, no. 2, pp. 115–121, 2003.

[10] W. S. Sly, M. P. Whyte, V. Sundaram et al., “Carbonic anhydrase II deficiency in 12 families with the autosomal recessive syndrome of osteopetrosis with renal tubular acidosis and cerebral calcification,” *The New England Journal of Medicine*, vol. 313, no. 3, pp. 139–145, 1985.

[11] A.-L. Du, H.-M. Ren, C.-Z. Lu, J.-L. Tu, C.-F. Xu, and Y.-A. Sun, “Carbonic anhydrase III is insufficient in muscles of myasthenia gravis patients,” *Autoimmunity*, vol. 42, no. 3, pp. 209–215, 2009.

[12] A. Du, S. Huang, X. Zhao et al., “Suppression of CHRN endocytosis by carbonic anhydrase CAR3 in the pathogenesis of myasthenia gravis,” *Autophagy*, vol. 13, no. 11, pp. 1981–1994, 2017.

[13] C. Diez-Fernandez, V. Rufenacht, S. Santra et al., “Defective hepatic bicarbonate production due to carbonic anhydrase VA deficiency leads to early-onset life-threatening metabolic crisis,” *Genetics in Medicine*, vol. 18, no. 10, pp. 991–1000, 2016.

[14] D. Avital, E. Hershkovitz, and N. Loewenthal, “Exertional rhabdomyolysis in carbonic anhydrase I2 deficiency,” *Journal of Pediatric Endocrinology and Metabolism*, vol. 31, no. 6, pp. 697–699, 2018.

[15] Y. Inagaki, Y. Jinno-Yoshida, Y. Hamasaki, and H. Ueki, “A novel autoantibody reactive with carbonic anhydrase in sera from patients with systemic lupus erythematosus and Sjögren’s syndrome,” *Journal of Dermatological Science*, vol. 2, no. 3, pp. 147–154, 1991.

[16] M. Robert-Pachot, A. Desbos, A. Moreira et al., “A new target for autoantibodies in patients with rheumatoid arthritis,” *Annals of the New York Academy of Sciences*, vol. 1108, pp. 382–391, 2007.
[17] A. Mentese, A. Alver, S. Demir et al., “Carbonic anhydrase i and ii autoantibodies in behçet’s disease,” Acta Reumatologica Portuguesa, vol. 2017, no. 1, pp. 26–31, 2017.

[18] F. Botrè, C. Botrè, E. Podestà, M. Poddà, and P. Invernizzi, “Effect of anti-carbonic anhydrase antibodies on carbonic anhydrases I and II,” Clinical Chemistry, vol. 49, no. 7, pp. 1221–1223, 2003.

[19] A. Mentese, E. Fidan, A. Alver et al., “Detection of autoantibodies against carbonic anhydrase I and II in the plasma of patients with gastric cancer,” Central European Journal of Immunology, vol. 42, no. 1, pp. 73–77, 2007.

[20] A. Alver, A. Mentese, S. C. Karahan et al., “Increased serum anti-carbonic anhydrase II antibodies in patients with Graves’ disease,” Experimental and Clinical Endocrinology & Diabetes, vol. 115, no. 5, pp. 287–291, 2007.

[21] A. Mentese, E. Fidan, A. Alver et al., “Autoantibodies against Carbonic Anhydrase I and II in Patients with Acute Myeloid Leukemia,” Turkish Journal of Hematology, 2017.

[22] M. Pertovaara, F. Bootorabi, M. Kuuslahti, A. Pasternack, and S. Parkkila, “Novel carbonic anhydrase autoantibodies and renal manifestations in patients with primary Sjögren’s syndrome,” Rheumatology, vol. 50, no. 8, pp. 1453–1457, 2011.

[23] F. Takemoto, H. Katori, N. Sawa et al., “Induction of anti-carbonic-anhydrase-II antibody causes renal tubular acidosis in a mouse model of Sjögren’s syndrome;” Nerophysiology, vol. 106, no. 4, pp. p63–p68, 2007.

[24] A. Alver, A. Mentese, U. Mentese, A. Sümér, F. Uçar, and D. Us Altay, “Anti-carbonic anhydrase ii antibodies in end-stage renal disease patients,” Medical Principles and Practice, vol. 023, no. 4, pp. 331–335, 2014.

[25] G. Adamus and L. Karren, “Autoimmunity against carbonic anhydrase II affects retinal cell functions in autoimmune retinopathy,” Journal of Autoimmunity, vol. 32, no. 2, pp. 133–139, 2009.

[26] S. Karakus, A. N. Baer, D. Agrawal, M. Gurakar, R. W. Massof, and E. K. Akpek, “Utility of Novel Autoantibodies in the Diagnosis of Sjögren’s Syndrome Among Patients With Dry Eye;” Cornea, vol. 37, no. 4, pp. 405–411, 2018.

[27] L. Phung, I. V. Lollett, R. Goldhardt et al., “Parallel ocular and serologic course in a patient with early Sjögren’s syndrome markers,” American Journal of Ophthalmology Case Reports, vol. 8, pp. 48–52, 2017.

[28] F. Guarneri, C. Guarneri, and S. Benvengra, “Helicobacter pylori and autoimmune pancreatitis: role of carbonic anhydrase via molecular mimicry?” Journal of Cellular and Molecular Medicine, vol. 9, no. 3, pp. 741–744, 2005.

[29] Author: Fvasconcellos Source; Public Domain, 2011, https://commons.wikimedia.org/wiki/File:Carbonic_anhydrase_1CA2.png.

[30] N. Merezhinskaya, S. A. Ogumwuyi, and W. N. Fishbein, “Expression of monocarboxylate transporter 4 in human platelets, leukocytes, and tissues assessed by antibodies raised against terminal versus pre-terminal peptides,” Molecular Genetics and Metabolism, vol. 87, no. 2, pp. 152–161, 2006.

[31] I. A. Ferreira, A. I. M. Mocking, R. T. Urbanus, S. Varlack, M. Wnuk, and J.-W. N. Akerman, “Glucose uptake via glucose transporter 3 by human platelets is regulated by protein kinase B,” The Journal of Biological Chemistry, vol. 280, no. 38, pp. 32625–32633, 2005.

[32] D. Rossskopf, “Sodium-hydrogen exchange and platelet function,” Journal of Thrombosis and Thrombolysis, vol. 8, no. 1, pp. 15–23, 1999.

[33] S. Gambaryan and D. Tsikas, “A review and discussion of platelet nitric oxide and nitric oxide synthase: do blood platelets produce nitric oxide from l-arginine or nitrite?” Amino Acids, vol. 47, no. 9, article no. 1986, pp. 1779–1793, 2015.

[34] K. Broos, H. B. Feys, S. F. De Meyer, K. Vanhoorebeke, and H. Deckmyn, “Platelets at work in primary hemostasis;” Blood Reviews, vol. 25, no. 4, pp. 155–167, 2010.

[35] E. H. Lieberman, S. O’Neill, and M. E. Mendelsohn, “S-nitrosothiol inhibition of human platelet secretion is correlated with increases in platelet cGMP levels,” Circulation Research, vol. 68, no. 6, pp. 1722–1728, 1991.

[36] E. Hanff, A. Böhmer, M. Zinke et al., “Carbonic anhydrases are producers of S-nitrosothiols from inorganic nitrate and modulators of soluble guanylyl cyclase in human platelets,” Amino Acids, vol. 48, no. 7, pp. 1695–1706, 2016.

[37] S. S. Smyth, S. Whiteheart, E. I. Joseph, and S. Barry, Platelet morphology, biochemistry and function; In: Williams Hematology by Marshall A. Lichtman, Thomas J. Kipps, Uri Seligsohn, Kenneth Kaushansky, Josef T. Prchal, 2010.

[38] C. T. Supuran, “Carbonic anhydrases: novel therapeutic applications for inhibitors and activators,” Nature Reviews Drug Discovery, vol. 7, no. 2, pp. 168–181, 2008.

[39] C. T. Supuran, “Acetazolamide for the treatment of idiopathic intracranial hypertension,” Expert Review of Neurotherapeutics, vol. 15, no. 8, pp. 851–856, 2015.

[40] H. Liu, I. Chiang, K. N. Kuo, C. Liou, and C. Chen, “The effect of acetazolamide on sleep apnea at high altitude: a systematic review and meta-analysis,” Therapeutic Advances in Respiratory Disease, vol. 11, no. 1, pp. 20–29, 2016.

[41] E. R. Swenson, “Carbonic Anhydrase Inhibitors and High Altitude Illnesses,” in Carbonic Anhydrase: Mechanism, Regulation, Links to Disease, and Industrial Applications, vol. 75 of Subcellular Biochemistry, pp. 361–386, Springer Netherlands, Dordrecht, 2014.

[42] D. Schmidl, L. Schmetterer, G. Garhöfer, and A. Popacherecheau, “Pharmacotherapy of Glaucoma,” Journal of Ocular Pharmacology and Therapeutics, vol. 31, no. 2, pp. 63–77, 2015.

[43] W. G. Reiss and K. S. Oles, “Acetazolamide in the Treatment of Seizures,” Annals of Pharmacotherapy, vol. 30, no. 5, pp. 514–519, 2016.

[44] J. L. Bryant, R. G. Gieling, S. L. Meredith et al., “Novel carbonic anhydrase IX-targeted therapy enhances the anti-tumour effects of cisplatin in small cell lung cancer,” International Journal of Cancer, vol. 142, no. 1, pp. 191–201, 2018.

[45] S. Lindskog, “Structure and mechanism of Carbonic Anhydrase;” Pharmacology & Therapeutics, vol. 74, no. 1, pp. 1–20, 1997.

[46] H. Nakai, M. G. Byers, P. J. Venta, R. E. Tashian, and T. B. Shows, “The gene for human carbonic anhydrase ii (Ca2) is located at chromosome 8q22;” Cytogenetic and Genome Research, vol. 44, no. 4, pp. 234–235, 1987.

[47] C. Sobacchi, A. Schulz, F. P. Coxon, A. Villa, and M. H. Hellrich, “Osteopetrosis: genetics, treatment and new insights into osteoclast function,” Nature Reviews Endocrinology, vol. 9, no. 9, pp. 522–536, 2013.

[48] Y. Imai, M.-Y. Youn, K. Inoue, I. Takada, A. Kouzmenko, and C. T. Supuran, “Activation of carbonic anhydrase isozymes,” in The Carbonic Anhydrases, W. R. Chegwidden, N. D. Carter, and Y. H. Edwards, Eds., vol. 90, EXS 90, Birkhäuser, Basel, 2000.
[50] C. T. Supuran, "How many carbonic anhydrase inhibition mechanisms exist?" Journal of Enzyme Inhibition and Medicinal Chemistry, vol. 31, no. 3, pp. 345–360, 2015.

[51] C. Temperini, A. Cecchi, A. Scozzafava, and C. T. Supuran, "Carbonic anhydrase inhibitors. Interaction of indapamide and related diuretics with 12 mammalian isozymes and X-ray crystallographic studies for the indapamide-isozyme II adduct," Bioorganic & Medicinal Chemistry Letters, vol. 18, no. 8, pp. 2567–2573, 2008.

[52] M.-C. Saada, D. Vullo, J.-L. Montero, A. Scozzafava, C. T. Supuran, and J.-Y. Winum, "Mono- and di-halogenated histamine, histidine and carnosine derivatives are potent carbonic anhydrase I, II, VII, XII and XIV activators," Bioorganic & Medicinal Chemistry, vol. 22, no. 17, pp. 4752–4758, 2014.

[53] F. Belloni and R. Turpini, "Presence of carbonic anhydrase in human platelets," Haematologica, vol. 42, no. 3, pp. 217–225, 1957.

[54] W. Siffert and G. Gros, "Carbonic anhydrase in human platelets," Biochemical Journal, vol. 217, no. 3, pp. 727–730, 1984.

[55] H. Vaitkevicius, I. Turner, A. Spalding, and W. Lockette, "Chloride increases adrenergic receptor-mediated platelet and vascular responses," American Journal of Hypertension, vol. 15, no. 6, pp. 492–498, 2002.

[56] E. K. Novak, H. O. Sweet, M. Prochazka et al., "Cocoa: A new mouse model for platelet storage pool deficiency," British Journal of Haematology, vol. 69, no. 3, pp. 371–378, 1988.

[57] J. W. N. Akkerman, H. Holmsen, and M. Loughnane, "Simultaneous measurement of aggregation, secretion, oxygen uptake, proton production, and intracellular metabolites in the same platelet suspension," Analytical Biochemistry, vol. 97, no. 2, pp. 387–393, 1979.

[58] J. W. N. Akkerman and H. Holmsen, "Interrelationships among platelet responses: Studies on the burst in proton liberation, lactate production, and oxygen uptake during platelet aggregation and Ca2+ secretion," Blood, vol. 57, no. 5, pp. 956–966, 1981.

[59] W. Siffert, G. Fox, and G. Gros, "Carbonic Anhydrase in Human Platelets: Effects of Carbonic Anhydrase Inhibition on Platelet Aggregation," Annals of the New York Academy of Sciences, vol. 429, no. 1, pp. 207–209, 1984.

[60] W. Siffert, G. Fox, and G. Gros, "The effect of carbonic anhydrase inhibition on the velocity of thrombin-stimulated platelet aggregation under physiological conditions," Biochemical and Biophysical Research Communications, vol. 121, no. 1, pp. 266–270, 1984.

[61] C. Temperini, A. Innocenti, A. Scozzafava, A. Mastrolorenzo, and C. T. Supuran, "Carbonic anhydrase activators: l-Adrenaline plucks the active site entrance of isozyme II, activating better isoforms I, IV, V, VII, and XIV," Bioorganic & Medicinal Chemistry Letters, vol. 17, no. 9, pp. 628–635, 2007.

[62] C. Temperini, A. Scozzafava, and C. T. Supuran, "Carbonic anhydrase activation and the drug design," Current Pharmaceutical Design, vol. 14, no. 7, pp. 708–715, 2008.

[63] A. Spalding, H. Vaitkevicius, S. Dill, S. MacKenzie, A. Schmaier, and W. Lockette, "Mechanism of epinephrine-induced platelet aggregation," Hypertension, vol. 31, no. 2, pp. 603–607, 1998.

[64] R. Woodman, C. Brown, and W. Lockette, "Chlorthalidone decreases platelet aggregation and vascular permeability and promotes angiogenesis," Hypertension, vol. 56, no. 3, pp. 463–470, 2010.

[65] J. S. Berger, R. C. Becker, C. Kuhn, M. J. Helms, T. L. Ortel, and R. Williams, "Hyperreactive platelet phenotypes: Relationship to altered serotonin transporter number, transport kinetics and intrinsic response to adrenergic co-stimulation," Thrombosis and Haemostasis, vol. 109, no. 1, pp. 85–92, 2013.

[66] C. R. Benedict, B. Mathew, K. A. Rex, J. Cartwright Jr., and L. A. Sordahl, "Correlation of plasma serotonin changes with platelet aggregation in an in vivo dog model of spontaneous occlusive coronary thrombus formation," Circulation Research, vol. 58, no. 1, pp. 58–67, 1986.

[67] K. Vikenes, M. Farstad, and J. E. Nordrehaug, "Serotonin is associated with coronary artery disease and cardiac events," Circulation, vol. 100, no. 5, pp. 483–489, 1999.

[68] I. Kajiwara, H. Soejima, S. Miyamoto, and H. Ogawa, "Effects of additional treatment of sarpogrelate to aspirin therapy on platelet aggregation and plasma plasminogen activator inhibitor activity in patients with stable effort angina," Thrombosis Research, vol. 128, no. 6, pp. 547–551, 2011.

[69] S. Uchiyama, Y. Ozaki, K. Satoh, K. Kondo, and K. Nishimaru, "Effect of sarpogrelate, a 5-HT2A antagonist, on platelet aggregation in patients with ischemic stroke: Clinical-pharmacological dose-response study," Cerebrovascular Disease, vol. 24, no. 2-3, pp. 264–270, 2007.

[70] K. Nishihira, A. Yamashita, N. Tanaka et al., "Inhibition of 5-hydroxytryptamine2A receptor prevents occlusive thrombus formation on neointima of the rabbit femoral artery," Journal of Thrombosis and Haemostasis, vol. 4, no. 1, pp. 247–255, 2006.

[71] A. Casini, S. Caccia, A. Scozzafava, and C. T. Supuran, "Carbonic anhydrase activators. The selective serotonin reuptake inhibitors fluoxetine, sertraline and citalopram are strong activators of isozymes I and II," Bioorganic & Medicinal Chemistry Letters, vol. 13, no. 16, pp. 2765–2768, 2003.

[72] N. Hergovich, M. Aigner, H.-G. Eichler, J. Entlicher, C. Drucker, and B. Ilmla, "Paroxetine decreases platelet serotonin storage and platelet function in human beings," Clinical Pharmacology & Therapeutics, vol. 68, no. 4, pp. 435–442, 2000.

[73] V. L. Serebrunay, P. A. Gurbel, and C. M. O’Connor, "Platelet inhibition by sertraline and N-desmethylsertraline: A possible missing link between depression, coronary events, and mortality benefits of selective serotonin reuptake inhibitors," Pharmacological Research, vol. 43, no. 5, pp. 453–461, 2001.

[74] T. C. van Holten, M. Roest, J. Riphagen et al., "Citalopram is a more potent platelet function inhibitor than paroxetine in a case-control study," Journal of Thrombosis and Haemostasis, vol. 10, no. 6, pp. 1177–1179, 2012.

[75] C. P. Alderman, C. K. Moritz, and D. I. Ben-Tovim, "Abnormal platelet aggregation associated with fluoxetine therapy," Annals of Pharmacotherapy, vol. 26, no. 12, pp. 1517–1519, 1992.

[76] C. R. Meier, R. G. Schlienger, and H. Jick, "Use of selective serotonin reuptake inhibitors and risk of developing first-time acute myocardial infarction," British Journal of Clinical Pharmacology, vol. 52, no. 2, pp. 179–184, 2001.

[77] M. M. Smith, B. B. Smith, B. D. Lahr et al., "Selective Serotonin Reuptake Inhibitors and Serotonin–Norepinephrine Reuptake Inhibitors Are Not Associated With Bleeding or Transfusion in Cardiac Surgical Patients," Anesthesiology, vol. 126, no. 6, pp. 1859–1866, 2018.

[78] E. Masini, M. G. Di Bello, S. Raspanti et al., "The role of histamine in platelet aggregation by physiological and immunological stimuli," Inflammation Research, vol. 47, no. 5, pp. 211–220, 1998.

[79] B. H. Shah, I. Lashari, S. Rana et al., "Synergistic interaction of adrenaline and histamine in human platelet aggregation is
mediated through activation of phospholipase, map kinase and cyclo-oxygenase pathways,” *Pharmacological Research*, vol. 42, no. 5, pp. 479–483, 2000.

[80] T. Zuberbier, D. Schadenhorf, N. Haas, K. Hartmann, and B. M. Heinz, "Enhanced P-Selectin Expression in Chronic and Dermographic Urticaria," *International Archives of Allergy and Immunology*, vol. 114, no. 1, pp. 86–89, 1997.

[81] L. Chandrashekar, M. Rajappa, I. Sundar et al., “Platelet activation in chronic urticaria and its correlation with disease severity,” *Platelets*, vol. 25, no. 3, pp. 162–165, 2014.

[82] T. Hallberg, M. Dohlsten, and B. Balandet, “Demonstration of Histamine Receptors on Human Platelets by Flow Cytometry,” *European Journal of Haematology*, vol. 32, no. 2, pp. 113–118, 1984.

[83] S. P. Saxena, L. J. Brandes, A. B. Becker, K. J. Simons, F. S. Labelle, and J. M. Gerrard, “Histamine is an intracellular messenger mediating platelet aggregation,” *Science*, vol. 243, no. 4898, pp. 1596–1599, 1989.

[84] S. P. Saxena, A. McNicol, L. J. Brandes, A. B. Becker, and J. M. Gerrard, “A role for intracellular histamine in collagen-induced platelet aggregation,” *Blood*, vol. 75, no. 2, pp. 407–414, 1990.

[85] S. Q. Li, G. Zhao, J. Li, and W. Qian, “Effect of histidine on myocardial mitochondria and platelet aggregation during thrombotic cerebral ischemia in rats,” *Zhongguo Yao Li Xue Bao*, vol. 19, no. 5, pp. 493–496, 1998.

[86] H. B. Steinruck, H. Kluft, L. Lubrich, and P. Schollmeyer, “Effect of L-histidine in vivo on human platelet function and arachidonic acid metabolism,” *Prostaglandins, Leukotrienes and Medicine*, vol. 18, no. 2, pp. 245–254, 1985.

[87] A. Boldyrev and H. Abe, “Metabolic transformation of neuropeptide carnosine modifies its biological activity,” *Cellular and Molecular Neurobiology*, vol. 19, no. 1, pp. 163–175, 1999.

[88] N. Nikitenko, V. Shavratskii, A. Boldyrev, Z. Suslina, and V. Ionova, “Effect of carnosine and its derivatives on ADP-induced human platelet aggregation (only abstract available),” *Voprosy Meditsinskoi Khimii*, vol. 41, no. 1, pp. 41–43, 1995.

[89] E. W. Salzman and D. A. Chambers, “Inhibition of ADP-induced platelet aggregation by substituted amino-acids [32],” *Nature*, vol. 204, no. 4959, pp. 698–700, 1964.

[90] N. C. Nayak, S. Roy, and T. K. Narayanan, “Pathologic features of altitude sickness,” *American Journal of Pathology*, vol. 45, pp. 381–391, 1964.

[91] S. C. Sharma and R. S. Hoon, “Platelet adhesiveness on acute induction to high altitude,” *Thrombosis Research*, vol. 13, no. 5, pp. 725–732, 1978.

[92] J. C. Chatterji, V. C. Ohri, B. K. Das et al., “Platelet count, platelet aggregation and fibrinogen levels following acute induction to high altitude (3200 and 3771 metres),” *Thrombosis Research*, vol. 26, no. 3, pp. 177–182, 1982.

[93] A. G. Vij, “Effect of prolonged stay at high altitude on platelet aggregation and fibrinogen levels,” *Platelets*, vol. 20, no. 6, pp. 421–427, 2009.

[94] R. H. G. O. Engberink, W. J. Frenkel, B. Van Den Bogaard, L. M. Brewster, L. Vogt, and B.-J. H. Van Den Born, “Effects of thiamide and thiadie-like diuretics on cardiovascular events and mortality: Systematic review and meta-analysis,” *Hypertension*, vol. 65, no. 5, pp. 1033–1040, 2015.

[95] F. Rendu, C. Bachelot, D. Mollé, J. Caen, and D. Guez, “Indapamide inhibits human platelet aggregation in vitro: Comparison with hydrochlorothiazide,” *Journal of Cardiovascular Pharmacology*, vol. 22, no. 12, pp. S57–S63, 1993.
[112] W. J. M. Dewilde, P. W. A. Janssen, T. O. Bergmeijer, J. C. Kelder, C. M. Hackeng, and J. M. ten Berg, “The effect of acenocoumarol on the antiplatelet effect of clopidogrel,” *Thrombosis and Haemostasis*, vol. 114, no. 4, pp. 708–716, 2015.

[113] A. Weber, A. Casini, A. Heine et al., “Unexpected Nanomolar Inhibition of Carbonic Anhydrase by COX-2-Selective Celecoxib: New Pharmacological Opportunities Due to Related Binding Site Recognition,” *Journal of Medicinal Chemistry*, vol. 47, no. 3, pp. 550–557, 2004.

[114] M. Katagiri, T. Ogasawara, K. Hoshi et al., “Suppression of adjuvant-induced arthritic bone destruction by cyclooxygenase-2-selective agents with and without inhibitory potency against carbonic anhydrase II,” *Journal of Bone and Mineral Research*, vol. 21, no. 2, pp. 219–227, 2006.

[115] A. Di Fiore, C. Pedone, K. D’Ambrosio, A. Scozzafava, G. De Simone, and C. T. Supuran, “Carbonic anhydrase inhibitors: Valdecoxib binds to a different active site region of the human isoform II as compared to the structurally related cyclooxygenase II ‘selective’ inhibitor celecoxib,” *Bioorganic & Medicinal Chemistry Letters*, vol. 16, no. 2, pp. 437–442, 2006.

[116] C. De Monte, S. Carradori, A. Gentili, A. Mollica, D. Trisciuoglio, and C. T. Supuran, “Dual cyclooxygenase and carbonic anhydrase inhibition by nonsteroidal anti-inflammatory drugs for the treatment of cancer,” *Current Medicinal Chemistry*, vol. 22, no. 24, pp. 2812–2818, 2015.

[117] I. M. Greene, M. Arifullah, and A. D. Kenny, “Carbonic anhydrase inhibition by flurbiprofen and related agents,” *Pharmacology*, vol. 45, no. 5, pp. 278–284, 1992.

[118] I. Puscas, M. Coltau, and R. Pasca, “Nonsteroidal anti-inflammatory drugs activate carbonic anhydrase by a direct mechanism of action,” *The Journal of Pharmacology and Experimental Therapeutics*, vol. 277, no. 3, pp. 1464–1466, 1996.

[119] I. Puscas, M. Ifrim, T. Maghiar et al., “Indomethacin activates carbonic anhydrase and antagonizes the effect of the specific carbonic anhydrase inhibitor acetazolamide, by a direct mechanism of action,” *International Journal of Clinical Pharmacology and Therapeutics*, vol. 39, no. 6, pp. 265–270, 2001.

[120] E. Bayram, M. Senturk, O. Ifran Kufrevioglu, and C. T. Supuran, “In vitro inhibition of salicylic acid derivatives on human cytosolic carbonic anhydrase isozymes I and II,” *Bioorganic & Medicinal Chemistry*, vol. 16, no. 20, pp. 9101–9105, 2008.

[121] A. J. Cummings and B. K. Martin, “The effect of acetylsalicylic acid on carbonic anhydrase in vitro,” *Biochemical Pharmacology*, vol. 12, no. 9, pp. 1011–1016, 1963.

[122] P. T. Leese, R. C. Hubbard, A. Karim, P. C. Isakson, S. S. Yu, and G. S. Geis, “Effects of celecoxib, a novel cyclooxygenase-2 inhibitor, on platelet function in healthy adults: A randomized, controlled trial,” *Clinical Pharmacology and Therapeutics*, vol. 40, no. 2, pp. 124–132, 2000.

[123] M. Jakubowski, J. Dębski, E. Szahidewicz-Krupska et al., “Platelet Carbonic Anhydrase II, a Forgotten Enzyme, May Be Responsible for Aspirin Resistance,” *Oxidative Medicine and Cellular Longevity*, vol. 2017, 2017.